BidaskClub Upgrades Hologic (HOLX) to Hold

BidaskClub upgraded shares of Hologic (NASDAQ:HOLX) from a sell rating to a hold rating in a report issued on Saturday.

A number of other analysts have also weighed in on the stock. Canaccord Genuity cut their price objective on shares of Hologic from $41.00 to $40.00 and set a hold rating on the stock in a research note on Thursday. Bank of America lowered shares of Hologic from a buy rating to a neutral rating and cut their price objective for the stock from $47.00 to $42.00 in a research note on Thursday. TheStreet lowered shares of Hologic from a b- rating to a c+ rating in a research note on Wednesday, September 5th. Barclays lowered shares of Hologic from an overweight rating to an equal weight rating and cut their price objective for the stock from $50.00 to $43.00 in a research note on Wednesday, September 5th. They noted that the move was a valuation call. Finally, Deutsche Bank cut their price objective on shares of Hologic from $45.00 to $43.00 and set a hold rating on the stock in a research note on Monday, August 20th. Ten equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Hologic has an average rating of Hold and a consensus target price of $44.47.

Shares of Hologic stock opened at $39.64 on Friday. The company has a current ratio of 1.29, a quick ratio of 0.99 and a debt-to-equity ratio of 1.12. Hologic has a 12-month low of $35.10 and a 12-month high of $45.09. The company has a market cap of $10.63 billion, a price-to-earnings ratio of 19.53, a P/E/G ratio of 1.78 and a beta of 0.65.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Tuesday, July 31st. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.02. Hologic had a negative net margin of 2.47% and a positive return on equity of 22.18%. The business had revenue of $824.00 million for the quarter, compared to analyst estimates of $800.14 million. research analysts forecast that Hologic will post 2.24 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Parnassus Investments CA boosted its holdings in Hologic by 3.4% during the second quarter. Parnassus Investments CA now owns 16,241,334 shares of the medical equipment provider’s stock worth $645,593,000 after buying an additional 535,745 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in Hologic by 5.1% during the second quarter. Victory Capital Management Inc. now owns 5,813,464 shares of the medical equipment provider’s stock worth $231,085,000 after buying an additional 282,510 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Hologic by 15.1% during the first quarter. Dimensional Fund Advisors LP now owns 2,301,792 shares of the medical equipment provider’s stock worth $85,995,000 after buying an additional 301,278 shares in the last quarter. Partner Fund Management L.P. boosted its holdings in Hologic by 20.3% during the second quarter. Partner Fund Management L.P. now owns 1,892,703 shares of the medical equipment provider’s stock worth $75,235,000 after buying an additional 319,846 shares in the last quarter. Finally, Guggenheim Capital LLC boosted its holdings in Hologic by 4.7% during the first quarter. Guggenheim Capital LLC now owns 1,739,642 shares of the medical equipment provider’s stock worth $64,993,000 after buying an additional 77,589 shares in the last quarter. 98.65% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Read More: Average Daily Trade Volume Explained

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply